3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: CC-220
DRUG: CC-220
DRUG: CC-220
DRUG: CC-220
DRUG: Placebo
DRUG: CC-220
DRUG: CC-220
DRUG: CC-220

Sponsor

Celgene Corporation